AFR - Why analysts love these eight medtech stocks

Nice little write up in the AFR today. Only a small section as part of a larger piece but hopefully get some exposure

Arovella Therapeutics: if this succeeds, it’s “probably the cheapest biotech stock in the world right now”, says portfolio manager Andrew Chapman of Merchant Funds Management. The Merchant Opportunities Fund – focused on medicine and biotechnology – has generated compound returns of 16.65 per cent per year for 10 years, compared to the S&P/ASX Small Ordinaries Index at 2.94 per cent per year to June 30, 2023.“[The therapy] is close to being fully developed,” says Chapman. “It’s trying to develop a cell that will go into your body and kill cancers. I really think this technology has the ability and potential to revolutionise the way we treat complex cancers.” Arovella shares fetched 18¢ on February 12, on a market value around $167 million.

Best-biotech-stocks-find-the-next-Pro-Medicus.pdf